Core Viewpoint - Viatris shares experienced a decline after six consecutive sessions of gains, closing at $10.13, which is a 0.6% decrease [1] Summary by Relevant Sections - **Stock Performance** - The stock gained 7% over the previous six sessions [1] - Year-to-date, the stock has lost over 13% [1] - In contrast, the broader market has risen by 14% [1]

Group 1 - The Conservative Income Portfolio focuses on value stocks with high margins of safety and aims to reduce volatility through well-priced options [1][2] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio aims for lower volatility income investing with an emphasis on capital preservation [1][2] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Group 1 - The Conservative Income Portfolio aims to target the best value stocks with high margins of safety while reducing volatility through well-priced options [1] - The Enhanced Equity Income Solutions Portfolio is designed to generate yields of 7-9% while minimizing volatility [1] - The Covered Calls Portfolio focuses on lower volatility income investing with an emphasis on capital preservation [1] Group 2 - Trapping Value is a team of analysts with over 40 years of combined experience in generating options income and capital preservation [2] - The investing group operates the Conservative Income Portfolio in partnership with Preferred Stock Trader, featuring two income-generating portfolios and a bond ladder [2]

Company Overview - Viatris Inc. (NASDAQ:VTRS) was formed from the 2020 merger of Mylan and Pfizer's Upjohn division, delivering essential generic and specialty medicines to patients in over 165 countries [1] - The company maintains a broad portfolio across multiple therapeutic areas, focusing on sustainable growth, operational discipline, and shareholder returns [1] Recent Developments - In September 2025, Viatris achieved FDA approval for its first generic Iron Sucrose Injection, a complex generic version of Venofer, which is intended for iron deficiency anemia in chronic kidney disease patients [2] - The injection is available in three strengths, with two awarded Competitive Generic Therapy designation, granting 180 days of market exclusivity [2] - Venofer generates $515 million in annual U.S. sales, and this approval significantly strengthens Viatris' injectable portfolio [2] Financial Performance - Viatris reported strong Q2 2025 results, with revenues of $3.58 billion and adjusted EPS of $0.62, exceeding expectations while maintaining top-half guidance for the year [3] - The firm returned over $630 million to shareholders year-to-date, including $350 million in share buybacks [3] Research and Development - Pipeline progress includes positive outcomes from five Phase 3 studies, notably in ophthalmic solutions for night vision impairment and presbyopia, supporting upcoming FDA submissions [3] - Presentations at PAINWeek 2025 highlighted Viatris' R&D capabilities and commitment to clinical innovation in pain management [4] Leadership Changes - Andrew Enrietti was appointed Chief Administrative and Transformation Officer, and David Simmons joined the board to strengthen strategic oversight [4]

Core Viewpoint - Viatris (NASDAQ: VTRS) experienced a 2.93% increase in stock price on Wednesday, reaching $9.84, after a significant decline over the previous seven trading sessions [1] Summary by Relevant Sections - Stock Performance - Over the past seven trading days, VTRS stock declined approximately 9% [1] - Notable daily losses included a 3.61% drop on September 15 and a 2.06% slide on September 12 [1]

Group 1 - Viatris Inc. is a global healthcare company formed from the merger of Mylan and Pfizer's Upjohn division in 2020, operating in over 165 countries and focusing on both generics and specialty pharmaceuticals [2] - The FDA approval of Viatris's first generic iron sucrose injection, a version of Venofer, is a significant development, with annual U.S. sales of approximately $515 million, marking an entry into the intravenous iron market [3] - Positive late-stage trial results for several pipeline assets, including fast-acting meloxicam for acute pain and the next-generation birth control patch XULANE LO, support the company's growth strategy and upcoming product launches through 2026 [4] Group 2 - Viatris's strategic emphasis on complex generics and specialty products indicates a shift from a primarily generic-focused business to a more innovation-driven company, highlighting the resilience of its diversified portfolio [5]

Core Viewpoint - The healthcare industry is currently facing significant challenges, with large-cap pharmaceutical companies particularly affected, leading to a poor performance compared to the market [2][3]. Group 1: Industry Challenges - The healthcare sector has only outperformed the market during downturns over the last decade, indicating a troubling trend [2]. - The current dynamics in the healthcare industry are described as the worst experienced in decades, with managed care and pharmaceuticals identified as the main contributors to market pressures [3]. Group 2: Investment Opportunities - A methodology was employed to identify cheap healthcare stocks, focusing on companies with a market capitalization above $2 billion and a forward P/E ratio below 15 [5]. - The article lists 12 healthcare stocks deemed attractive for investment, based on their valuation metrics and growth potential [6]. Group 3: Company Highlights - **Bausch Health Companies Inc. (NYSE:BHC)**: - Forward P/E Ratio: 1.45, recognized for strategic acquisitions and pipeline developments, particularly in hepatology [7]. - Recent acquisition of DURECT Corporation valued at $63 million upfront, with potential milestone payments of up to $350 million, enhancing its portfolio for alcoholic hepatitis [8]. - Key pipeline assets include larsucosterol and rifaximin SSD, with significant market potential in addressing hospitalizations for alcoholic hepatitis [9][10]. - **Organon & Co. (NYSE:OGN)**: - Forward P/E Ratio: 2.73, focused on women's health and biosimilars, expanding its market presence since spinning off from Merck [11]. - Recent FDA approvals for biosimilars BILDYOS and BILPREVDA, aimed at improving access to osteoporosis and bone cancer treatments [12]. - The company is pivoting towards biosimilars as a growth engine while maintaining focus on women's health and dermatology [13]. - **Viatris Inc. (NASDAQ:VTRS)**: - Forward P/E Ratio: 4.40, formed from the merger of Mylan and Pfizer's Upjohn division, focusing on generics and specialty pharmaceuticals [14]. - FDA approval of a generic iron sucrose injection, reflecting a strategic entry into the intravenous iron market with significant sales potential [15]. - Positive late-stage trial results for several pipeline assets, reinforcing the company's growth strategy and upcoming product launches [16][17].

Group 1 - Viatris Inc shares crossed below their 200-day moving average of $9.98, trading as low as $9.95 per share, reflecting a decline of approximately 1.9% on the day [2] - The 52-week range for VTRS shares is between a low of $6.85 and a high of $13.55, with the last trade recorded at $9.96 [2] - The data regarding VTRS's moving average was sourced from TechnicalAnalysisChannel.com [2]

Core Insights - The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund launched on May 1, 2006, aimed at providing broad exposure to the Healthcare - Pharma segment of the equity market [1] - The Healthcare - Pharma sector is ranked 7th among the 16 Zacks sectors, placing it in the top 44% [2] Fund Overview - Sponsored by Blackrock, IHE has assets exceeding $578.73 million, categorizing it as an average-sized ETF [3] - The fund seeks to match the performance of the Dow Jones U.S. Select Pharmaceuticals Index, which is a free-float adjusted market capitalization-weighted index [4] Cost Structure - IHE has an annual operating expense ratio of 0.38%, making it one of the cheaper options in the ETF space [5] - The ETF offers a 12-month trailing dividend yield of 1.64% [5] Sector Exposure and Holdings - The ETF is fully allocated to the Healthcare sector, with approximately 100% of its portfolio [6] - Johnson & Johnson (JNJ) constitutes about 25.45% of total assets, followed by Eli Lilly (LLY) and Viatris Inc (VTRS), with the top 10 holdings accounting for approximately 78.07% of total assets [7] Performance Metrics - As of September 2, 2025, IHE has gained roughly 9.19% this year but is down about 0.74% over the past year [8] - The ETF has traded between $61 and $72.85 in the last 52 weeks, with a beta of 0.54 and a standard deviation of 15.83% over the trailing three-year period, indicating a higher risk profile [8] Alternatives - IHE carries a Zacks ETF Rank of 3 (Hold), suggesting it is a reasonable option for investors seeking exposure to the Healthcare ETFs area [9] - Other ETF options include Invesco Pharmaceuticals ETF (PJP) and VanEck Pharmaceutical ETF (PPH), with respective assets of $259.99 million and $620.64 million [10]

Core Viewpoint - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] Group 1: Market Performance - Since reaching a historical high on September 3, 2024, healthcare stocks have been in a "persistent downtrend," underperforming both in absolute terms and relative to the S&P 500 [1] - August is identified as a turning point for the sector, with healthcare stocks beginning to reverse their previous weak performance [1] Group 2: Economic Environment - The recovery is driven by a historically significant valuation gap and an economic backdrop characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors the healthcare sector [1] - The dual effect of valuation discount and improved sentiment provides strong justification for including healthcare stocks in investment portfolios under the current economic conditions [2] Group 3: Investment Recommendations - Evercore ISI highlights several healthcare stocks with attractive valuations and sentiment, including Cencora (COR.US), BioMarin Pharmaceutical (BMRN.US), Cigna (CI.US), Cardinal Health (CAH.US), Humana (HUM.US), Incyte (INCY.US), LabCorp (LH.US), Pfizer (PFE.US), Quest Diagnostics (DGX.US), Teleflex (TFX.US), Tenet Healthcare (THC.US), Universal Health Services (UHS.US), and Viatris (VTRS.US) [2]